Medgenics Inc Preliminary Prospectus Supplement (8637V)
January 18 2013 - 2:10AM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 8637V
Medgenics Inc
18 January 2013
Press Release 18 January 2013
Medgenics, Inc.
(the "Company")
Preliminary Prospectus Supplement
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own
tissue, announces that it has filed with U.S. Securities and
Exchange Commission ("SEC") a Preliminary Prospectus Supplement,
updating the Prospectus dated 26 October, 2012 which forms part of
a "shelf" registration statement. The Preliminary Prospectus
Supplement can be viewed at the SEC's website at www.sec.gov.
- Ends -
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900
Dr. Andrew L. Pearlman
Andrew.pearlman@medgenics.com
Abchurch Communications Phone: +44 207 398 7719
Adam Michael
Joanne Shears
Jamie Hooper
jamie.hooper@abchurch-group.com
SVS Securities plc (Joint Broker) Phone: +44 207 638 5600
Alex Mattey
Ian Callaway
Nomura Code Securities (NOMAD/Broker) Phone: +44 207 776 1219
Jonathan Senior
Giles Balleny
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGIGDBXGBBGXI
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Medgenics(Regs) (London Stock Exchange): 0 recent articles
More Medgenics(Regs) News Articles